Lumenis Introduces the Lumenis Pulse(TM) 120H Holmium Laser Platform, the Most Powerful and Versatile Laser Surgery Solution in Urology

YOKNEAM, ISRAEL--(Marketwired - Apr 7, 2014) - Lumenis Ltd. (NASDAQ: LMNS), the world largest medical laser company for surgical, ophthalmology and aesthetic applications, announced today the introduction of the Lumenis Pulse™ 120H Holmium laser platform. With unrivaled power, speed, safety and versatility, the Lumenis Pulse™ 120H (120 W, 80 Hz and 6J) provides physicians performing urological procedures with a superior product enabling excellent clinical results and greater return on investment.

The new platform debuts at the 29th Annual European Association of Urology (EAU) Congress. Healthcare professionals attending EAU (April 11-15, 2014, Stockholm, Sweden) can learn more by visiting the Lumenis booth (# B04:49) for a product demonstration.

"The introduction* of the Pulse™ 120H is a major milestone for Lumenis," said Tzipi Ozer-Armon, CEO of Lumenis. "This platform provides a significant improvement to our current solutions for Enucleation and Flexible Ureteroscopy as well as extends our reach to address two important additional procedures of Vaporization and PCNL. Hence, this platform offers an attractive solution for four major urological procedures." 

Ozer-Armon added that "Our new superior platform along with new set of supplemental tools such as fibers, morcellator, training programs and simulator offers comprehensive solutions in Enucleation, Vaporization of the prostate, Stone Flexible Ureteroscopy and PCNL. We strongly believe that with this new set of tools we have the right answers for reducing procedure time, while enhancing procedures' safety and efficacy to address the needs of all the major stakeholders in the healthcare industry: patients, physicians, providers and insurers."

The Lumenis Pulse™ 120H is the optimal platform for preforming enhanced Vaporization, Enucleation, Flexible Ureteroscopy and Percutaneous Nephrolithotomy (PCNL) procedures.

Holmium Laser Enucleation of the Prostate (HoLEP)
"The Lumenis Pulse™ 120H will make HoLEP procedures more precise, faster and efficient," said Mr. Tev Aho, Consultant Urologist, Cambridge University NHS Trust, U.K. "When using the product, I found that no matter how fast I went with the enucleation, the hemostasis was excellent, the view was very good and it allowed me to significantly reduce procedure time."

Vaporization of the Prostate
"For Vaporization of the prostate, the Lumenis Pulse™ 120H stands apart from other available technologies and is clearly superior to KTP (GreenLight®** Laser) or TURP's," said Mr. Christof Kastner, Consultant Urologist, Cambridge University NHS Trust, UK. "Bleeding is minimal, tissue is easier to remove and, as we have experienced, patients can have their catheter removed almost immediately and go home the same day."

Stone-Dusting™ for Flexible Ureteroscopy and PCNL
"I believe that the development of the Lumenis Pulse 120H laser is definitely going to add to the armamentarium of the stone management," said Dr. Mahesh Desai, Medical Director, Muljibhai Patel Urological Hospital, India.

"The combination of suction with high energy laser to break the stones is innovative and very attractive," added Dr. Desai. "The laser would be faster in breaking the stone to powder than any other alternative. When using the embedded suction it definitely reduces the procedure duration and provides superior solution compare to what is currently available on the market, based on my personal experience, yet it requires a comparative study to prove it scientifically."

The Lumenis Pulse™ 120H Platform is accompanied by a range of new fibers and accessories, enabling improved clinical outcomes, reduced treatment time and increased patient satisfaction. They include:

• The Xpeeda™ fiber - improves energy utilization and accelerates vaporization rate.
• The SlimLine™ 200 fiber - sets new standards for flexibility, efficiency and durability, thus improving Stone-Dusting™ capabilities.
• The VersaCut+™ Tissue Morcellator***, which is safer, faster, more intuitive and cost-effective.
• A new simulator designed to train Urologists on the HoLEP procedure.
• The HoLEP Disposables Kit - contains all needed HoLEP instruments in one compact package.

The Lumenis Pulse™ 120H is the new addition to Lumenis comprehensive portfolio for BPH and stones laser-based solutions. Lumenis continues to offer the entire portfolio which includes, among others, the following platforms, to address various market needs:

• The VersaPulse® P20 (20W), which is a cost effective solution mainly for Stones;
  
  
• The VersaPulse® PowerSuite™ (100W), which is mainly used for Flexible Ureteroscopy, including stone dusting capabilities, and BPH Enucleation;
  
  
• The Lumenis Pulse™ 120H platform (120 W, 80 Hz and 6J), a comprehensive solution designated to be used for BPH Enucleation, Vaporization of the prostate, Stone Flexible Ureteroscopy, including stone dusting capabilities and PCNL.
  
  

Leaders of the European urology community will be conducting presentations and training sessions, including an instructional workshop reviewing the HoLEP procedure, throughout the EAU Annual Congress (please see full schedule of activities below).

Lumenis press event will be held on Sunday, April 13^th, at 11:15-12:15 in room K11.

Key Presentations Highlighting Lumenis Technologies at the 29th Annual EAU Congress

Holmium and Beyond: An Instructional Workshop
Sunday, April 13, 2014, 17:45 - 19:15, room K11 (within the congress centre)

Moderator: Rainer M. Kuntz, MD, PhD, Auguste Viktoria Hospital, Berlin

Subject		Speaker
"Mastering the HoLEP Technique"		Karin Lehrich, MD, Vivantes Auguste-Victoria-Hospital
"Holmium Versatility - Results From a Human Study"		Mahesh Desai, MD, Muljibhai Patel Urological Hospital
"HoLEP Experience in the UK: from Adoption to Gold Standard Technique"		Tev Aho, Cambridge Urology Partnership
"HoLEP: Overcoming the Learning Curve"		Gregoire Robert, MD, PhD, Bordeaux University Hospital
"HoLEP as a Day Case Technique and the Benefits for Your Patients and Hospital"		Mark Cynk, Spire Tunbridge Wells Hospital

Expert led HoLEP simulations will be held twice a day during April 12-14th / 11:00 - 15:00
Secure your HoLEP session and register: http://information.lumenis.com/eau-2014-pre-registration-for-the-holep-simulator.

Meet-the-Expert
Visit Lumenis at the EAU and grab the opportunity to engage in a 1:1 meeting with an expert in the procedure.

Expert	Time
Mr. Mark Cynk, UK	Saturday, April 12th 1400-1500
Mr. Tev Aho, UK	Sunday, April 13th 1400-1500
Mr. Gerald Rix, UK	Monday, April 14th 1400-1500

The Lumenis Pulse™ 120H platform will also be featured at the Lumenis booth (#1235) at the American Urology Association's 2014 Annual Meeting from May 16-21, 2014, in Orlando, Florida.

About Lumenis
Lumenis (NASDAQ: LMNS) is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods in each and every one of the verticals we operate in. Our drive for innovation stems from an uncompromising commitment to improving the health and well-being of our patients; addressing new and growing needs of aging populations; and in offering medical professionals cutting-edge solutions that fit seamlessly into the health-economics environment of the 21st century. The world over, we bring Energy to Healthcare.
For more information visit: www.lumenis.com

* The Lumenis Pulse™ 120H is a CE & FDA approved device
**Greenlight is a registered trademark of Laserscope Corporation
***The VersaCut+ Tissue Morcellator is approved for sale in Europe and is pending FDA clearance for the United States market.